Vimta Labs Ltd

Stage 3 · Topping · week 1⚠ 2→3 today

As of 16 Oct 2026, Vimta Labs is in Stage 3 — topping, where an uptrend loses steam, in its first week (since 16 Oct 2026). It closed at ₹522, 28.0% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.0% of stocks are in Stage 2.

Vimta Labs Limited provides contract research and testing services in India and internationally. More about the company

₹522.5
+0.15% today
₹2,335 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dLabs & Life Sciences Services 16.7%-16.7 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is VIMTALABS early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-28.0%
₹380.7 lo₹725.4 hi
28.0% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 1
1w13w26w
Week 1 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-1.6%
200 DMA: ₹530.7 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.26x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -6.5% vs MA50 -0.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-12.7%
3M
-6.6%
6M
+10.3%
YTD
-15.6%
1Y
-29.9%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 66 Stage 2 leaders. See Health Care Stage 2 →
Industry
Labs & Life Sciences Services
↓ Peaking
Stage 2%
16.7%
20d Δ
-16.7pp
1M return
+0.0%
3M return
+23.4%
Industry Stage-2 % · last 20 days
Industry has 1 Stage 2 leader. See Labs & Life Sciences Services Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 16w
S2 40w
S2 16w
S4 14w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 16w → S3 7w → S4 6w → S1 8w → S2 6w → S1 3w → S2 40w → S3 1w → S2 11w → S3 7w → S2 16w → S3 10w → S4 14w → S1 12w → S2 11w → S3 1w current
Total tracked: 168 weeks across 16 stage runs.
Scan Membership
Prop Scan
Latest: 2026-09-21
Breakout Watch
Latest: 2026-07-29
37 appearances in last 60 days. First seen: 2024-04-04.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S32→3
Wk 1 · Vol 0.26x
2026-10-15S2
Wk 11 · Vol 0.48x
2026-10-14S2
Wk 11 · Vol 0.45x
2026-10-13S2
Wk 11 · Vol 0.79x
2026-10-12S2
Wk 11 · Vol 0.28x
2026-10-09S2
Wk 11 · Vol 0.59x
2026-10-08S2
Wk 10 · Vol 0.49x
2026-10-07S2
Wk 10 · Vol 0.60x
2026-10-06S2
Wk 10 · Vol 0.59x
2026-10-05S2
Wk 10 · Vol 0.40x
2026-10-01S2
Wk 10 · Vol 0.38x
2026-09-30S2
Wk 9 · Vol 0.51x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹607.6
200 DMA
₹530.7
52W High
₹725.4
52W Low
₹380.7
5D Low
₹521.7
Resistance levels (recent highs)
20d High
₹617.2
60d High
₹661.8
120d High
₹661.8
250d High
₹725.4
Next resistance
+18.1%
to 20d High
Ask the Market AI about VIMTALABSAsk →
P/E (TTM)
26.6
Forward —
Earnings Growth (YoY)
+18.2%
Revenue +14.0%
ROE
+18.6%
Profit margin +19.0%
Dividend Yield
0.43%
P/B 4.9
About this companyHealth Care· Labs & Life Sciences Services

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.